Nivagen accuses India-based big pharma of ‘meddling’ in patent application
Sun Pharma’s Sezaby, used to treat infant seizures, infringes two patents says Nivagen | US firm accuses Indian rival of attempting to block patent from issuing.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
24 August 2023 Indian drugmaker had challenged PTAB decision that patent for new version of ruxolitinib was invalid as obvious | Decision hands a victory to US rival.
24 March 2022 Sun Pharmaceuticals has agreed to pay $485 million to settle an antitrust lawsuit relating to a generic drug application filed by its subsidiary, Ranbaxy, ending years of litigation.